Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III trial of MicroProst in patients with Chronic Angle Closure Glaucoma (CACG)

Next Previous
Trial Profile

A phase III trial of MicroProst in patients with Chronic Angle Closure Glaucoma (CACG)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 19 Feb 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Latanoprost (Primary)
  • Indications Angle-closure glaucoma
  • Focus Therapeutic Use

Most Recent Events

  • 13 Feb 2019 According to an Eyenovia Inc. media release, the company will initiate First Patient In H1 2019.
  • 13 Feb 2019 According to an Eyenovia Inc. media release, following discussions with the U.S. Food and Drug Administration (FDA), the study population will include chronic angle closure glaucoma (CACG), as well as open angle glaucoma (OAG) and ocular hypertension (OHT) patients
  • 14 Aug 2018 According to an Eyenovia Inc. media release, the trial will initiate in H1 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top